Assessment of the effect of an enhanced prior authorization and management program in a United States Medicaid program on chronic hepatitis C treatment adherence and cost

0
0 / 5 (0 votos)

Journal of the American Pharmacists Association

Fecha de publicación: 14 june 2018

DOI: https://doi.org/10.1016/j.japh.2018.06.013

Autores: Shellie L. Keast, Bethany Holderread, Terry Cothran, Grant H. Skrepnek

Background: The market for chronic hepatitis C (HCV) treatment has changed rapidly. New treatments offer high cure rates, fewer adverse effects, and shorter treatments—but also increased costs per therapy. The objective of this study was to compare adherence and cost between HCV patients included in an enhanced prior authorization and management program (PAMP) versus no intervention in Medicaid members undergoing treatment.

Seguir leyendo